Pharma Mar Announces Positive Trial Results for Cancer Drug
Company Announcements

Pharma Mar Announces Positive Trial Results for Cancer Drug

Pharma Mar SA (ES:PHM) has released an update.

Pharma Mar and Jazz Pharmaceuticals have announced promising phase III trial results for their drug combination of Zepzelca® and atezolizumab, which significantly improves survival rates for patients with advanced stage small cell lung cancer. The companies plan to seek regulatory approval in the U.S. and Europe by 2025, highlighting a potential new treatment option for this aggressive cancer. These findings could offer a much-needed advancement in extending patient survival.

For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Spain Auto-Generated NewsdeskPharma Mar Hits $10 Million Milestone with Janssen
TipRanks Auto-Generated NewsdeskPharma Mar SA Reports Strong Revenue Growth in 2024
TipRanks Spain Auto-Generated NewsdeskPharma Mar S.A. Announces Strategic Share Capital Reduction
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App